Login Register Cart 0
Review Article

LncRNA MIAT在糖尿病并发症中的作用

卷 31, 期 13, 2024

发表于: 21 September, 2023

页: [1716 - 1725] 页: 10

弟呕挨: 10.2174/0929867331666230914091944

价格: $65

Open Access Journals Promotions 2
conference banner
摘要

长链非编码RNA (Long non-coding RNA, LncRNA)是指一大类不具有编码蛋白质功能的RNA，其核苷酸超过200个。近年来，越来越多的文献揭示lncRNA参与操纵与人类健康和疾病相关的基因，发挥着突出的生物学功能，引起了研究者的广泛关注。新发现的长链非编码RNA心肌梗死相关转录物(LncRNA MIAT)在多种疾病，特别是糖尿病并发症中异常表达，并已被证明具有广泛的作用。本文旨在综述LncRNA MIAT在糖尿病心肌病、糖尿病肾病、糖尿病视网膜病变等糖尿病并发症中的重要作用，并重点介绍其参与调节糖尿病并发症的途径和机制的最新发现，以期为糖尿病并发症的治疗寻找新的干预靶点。LncRNA MIAT竞争性结合microrna作为竞争性内源rna调节基因表达。因此，本文综述了LncRNA MIAT在糖尿病并发症中的生物学功能和发病机制，并阐述了其在糖尿病并发症中的作用。这将有助于发现新的糖尿病并发症的治疗靶点和干预策略。

关键词: LncRNA, MIAT，血管病变，糖尿病，并发症，功能，机制。

« Previous Next »
[1]
Kallapur, A.; Sallam, T. Endothelial cells LEENE on noncoding RNAs in diabetic vasculopathy. J. Clin. Invest., 2023, 133(3), e167047.
[http://dx.doi.org/10.1172/JCI167047] [PMID: 36719373]
[2]
Da, C.; Gong, C.Y.; Nan, W.; Zhou, K.S.; Wu, Z.L.; Zhang, H.H. The role of long non-coding RNA MIAT in cancers. Biomed. Pharmacother., 2020, 129, 110359.
[http://dx.doi.org/10.1016/j.biopha.2020.110359] [PMID: 32535389]
[3]
Ishii, N.; Ozaki, K.; Sato, H.; Mizuno, H.; Susumu Saito; Takahashi, A.; Miyamoto, Y.; Ikegawa, S.; Kamatani, N.; Hori, M.; Satoshi, S.; Nakamura, Y.; Tanaka, T. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J. Hum. Genet., 2006, 51(12), 1087-1099.
[http://dx.doi.org/10.1007/s10038-006-0070-9] [PMID: 17066261]
[4]
Liao, J.; He, Q.; Li, M.; Chen, Y.; Liu, Y.; Wang, J. LncRNA MIAT: Myocardial infarction associated and more. Gene, 2016, 578(2), 158-161.
[http://dx.doi.org/10.1016/j.gene.2015.12.032] [PMID: 26707210]
[5]
Galaviz, K.I.; Weber, M.B.; Straus, A.; Haw, J.S.; Narayan, K.M.V.; Ali, M.K. Global diabetes prevention interventions: A systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care, 2018, 41(7), 1526-1534.
[http://dx.doi.org/10.2337/dc17-2222] [PMID: 29934481]
[6]
Alfaifi, M.; Ali Beg, M.M.; Alshahrani, M.Y.; Ahmad, I.; Alkhathami, A.G.; Joshi, P.C.; Alshehri, O.M.; Alamri, A.M.; Verma, A.K. Circulating long non-coding RNAs NKILA, NEAT1, MALAT1, and MIAT expression and their association in type 2 diabetes mellitus. BMJ Open Diabetes Res. Care, 2021, 9(1), e001821.
[http://dx.doi.org/10.1136/bmjdrc-2020-001821] [PMID: 33436407]
[7]
Boon, R.A.; Jaé, N.; Holdt, L.; Dimmeler, S. Long noncoding RNAs. J. Am. Coll. Cardiol., 2016, 67(10), 1214-1226.
[http://dx.doi.org/10.1016/j.jacc.2015.12.051] [PMID: 26965544]
[8]
Li, Y.; Li, J.; Chen, L.; Xu, L. The roles of long non-coding RNA in osteoporosis. Curr. Stem Cell Res. Ther., 2020, 15(7), 639-645.
[http://dx.doi.org/10.2174/1574888X15666200501235735] [PMID: 32357819]
[9]
Mattick, J.S.; Amaral, P.P.; Carninci, P.; Carpenter, S.; Chang, H.Y.; Chen, L.L.; Chen, R.; Dean, C.; Dinger, M.E.; Fitzgerald, K.A.; Gingeras, T.R.; Guttman, M.; Hirose, T.; Huarte, M.; Johnson, R.; Kanduri, C.; Kapranov, P.; Lawrence, J.B.; Lee, J.T.; Mendell, J.T.; Mercer, T.R.; Moore, K.J.; Nakagawa, S.; Rinn, J.L.; Spector, D.L.; Ulitsky, I.; Wan, Y.; Wilusz, J.E.; Wu, M. Long non-coding RNAs: Definitions, functions, challenges and recommendations. Nat. Rev. Mol. Cell Biol., 2023, 24(6), 430-447.
[http://dx.doi.org/10.1038/s41580-022-00566-8] [PMID: 36596869]
[10]
Ghafouri-Fard, S.; Khoshbakht, T.; Hussen, B.M.; Taheri, M.; Arefian, N. Regulatory role of non-coding RNAs on immune responses during sepsis. Front. Immunol., 2021, 12, 798713.
[http://dx.doi.org/10.3389/fimmu.2021.798713] [PMID: 34956235]
[11]
Tofigh, R.; Hosseinpourfeizi, M.; Baradaran, B.; Teimourian, S.; Safaralizadeh, R. Rheumatoid arthritis and non-coding RNAs; how to trigger inflammation. Life Sci., 2023, 315, 121367.
[http://dx.doi.org/10.1016/j.lfs.2023.121367] [PMID: 36639050]
[12]
Kretz, M.; Siprashvili, Z.; Chu, C.; Webster, D.E.; Zehnder, A.; Qu, K.; Lee, C.S.; Flockhart, R.J.; Groff, A.F.; Chow, J.; Johnston, D.; Kim, G.E.; Spitale, R.C.; Flynn, R.A.; Zheng, G.X.Y.; Aiyer, S.; Raj, A.; Rinn, J.L.; Chang, H.Y.; Khavari, P.A. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature., 2013, 493(7431), 231-235.
[http://dx.doi.org/10.1038/nature11661] [PMID: 23201690]
[13]
Vance, K.W.; Ponting, C.P. Transcriptional regulatory functions of nuclear long noncoding RNAs. Trends Genet., 2014, 30(8), 348-355.
[http://dx.doi.org/10.1016/j.tig.2014.06.001] [PMID: 24974018]
[14]
Yu, B.; Wang, S. Angio-LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics, 2018, 8(13), 3654-3675.
[http://dx.doi.org/10.7150/thno.26024] [PMID: 30026873]
[15]
Ballantyne, M.D.; McDonald, R.A.; Baker, A.H. lncRNA/MicroRNA interactions in the vasculature. Clin. Pharmacol. Ther., 2016, 99(5), 494-501.
[http://dx.doi.org/10.1002/cpt.355] [PMID: 26910520]
[16]
Cech, T.R.; Steitz, J.A. The noncoding RNA revolution- trashing old rules to forge new ones. Cell, 2014, 157(1), 77-94.
[http://dx.doi.org/10.1016/j.cell.2014.03.008] [PMID: 24679528]
[17]
Ahn, Y.H.; Kim, J.S. Long non-coding RNAs as regulators of interactions between cancer-associated fibroblasts and cancer cells in the tumor microenvironment. Int. J. Mol. Sci., 2020, 21(20), 7484.
[http://dx.doi.org/10.3390/ijms21207484] [PMID: 33050576]
[18]
Paldino, G.; Fierabracci, A. Shedding new light on the role of ERAP1 in Type 1 diabetes: A perspective on disease management. Autoimmun. Rev., 2023, 22(4), 103291.
[http://dx.doi.org/10.1016/j.autrev.2023.103291] [PMID: 36740089]
[19]
Kim, D.H.; Park, J.S.; Choi, H.I.; Kim, C.S.; Bae, E.H.; Ma, S.K.; Kim, S.W. The role of the farnesoid X receptor in kidney health and disease: A potential therapeutic target in kidney diseases. Exp. Mol. Med., 2023, 55(2), 304-312.
[http://dx.doi.org/10.1038/s12276-023-00932-2] [PMID: 36737665]
[20]
Jiang, S.; Fang, J.; Li, W. Protein restriction for diabetic kidney disease. Cochrane Libr., 2023, 2023(1), CD014906.
[http://dx.doi.org/10.1002/14651858.CD014906.pub2] [PMID: 36594428]
[21]
Lim, L.L.; Chow, E.; Chan, J.C.N. Cardiorenal diseases in type 2 diabetes mellitus: Clinical trials and real-world practice. Nat. Rev. Endocrinol., 2023, 19(3), 151-163.
[http://dx.doi.org/10.1038/s41574-022-00776-2] [PMID: 36446898]
[22]
Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol., 2018, 14(2), 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[23]
Zhao, X.; Ling, F.; Zhang, G.; Yu, N.; Yang, J.; Xin, X. The correlation between MicroRNAs and diabetic retinopathy. Front. Immunol., 2022, 13, 941982.
[http://dx.doi.org/10.3389/fimmu.2022.941982] [PMID: 35958584]
[24]
Zhu, J.; Han, J.; Liu, L.; Liu, Y.; Xu, W.; Li, X.; Yang, L.; Gu, Y.; Tang, W.; Shi, Y.; Ye, S.; Hua, F.; Xiang, G.; Liu, M.; Sun, Z.; Su, Q.; Li, X.; Li, Y.; Li, Y.; Li, H.; Li, Y.; Yang, T.; Yang, J.; Shi, L.; Yu, X.; Chen, L.; Shao, J.; Liang, J.; Han, X.; Xue, Y.; Ma, J.; Zhu, D.; Mu, Y. Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 2023, 197, 110568.
[http://dx.doi.org/10.1016/j.diabres.2023.110568] [PMID: 36738836]
[25]
Dwivedi, K.K.; Lakhani, P.; Sihota, P.; Tikoo, K.; Kumar, S.; Kumar, N. The multiscale characterization and constitutive modeling of healthy and type 2 diabetes mellitus Sprague Dawley rat skin. Acta Biomater., 2022, 158, 324-346.
[http://dx.doi.org/10.1016/j.actbio.2022.12.037] [PMID: 36565785]
[26]
Liu, M.; Peng, T.; Hu, L.; Wang, M.; Guo, D.; Qi, B.; Ren, G.; Wang, D.; Li, Y.; Song, L.; Hu, J.; Li, Y. N-glycosylation-mediated CD147 accumulation induces cardiac fibrosis in the diabetic heart through ALK5 activation. Int. J. Biol. Sci., 2023, 19(1), 137-155.
[http://dx.doi.org/10.7150/ijbs.77469] [PMID: 36594096]
[27]
Zhou, X.; Zhang, W.; Jin, M.; Chen, J.; Xu, W.; Kong, X. lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. Cell Death Dis., 2017, 8(7), e2929.
[http://dx.doi.org/10.1038/cddis.2017.321] [PMID: 28703801]
[28]
Pant, T.; Dhanasekaran, A.; Fang, J.; Bai, X.; Bosnjak, Z.J.; Liang, M.; Ge, Z.D. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy. BMC Cardiovasc. Disord., 2018, 18(1), 197.
[http://dx.doi.org/10.1186/s12872-018-0939-5] [PMID: 30342478]
[29]
Sohrabifar, N.; Ghaderian, S.M.H.; Alipour Parsa, S.; Ghaedi, H.; Jafari, H. Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus. Arch. Physiol. Biochem., 2022, 128(5), 1308-1315.
[http://dx.doi.org/10.1080/13813455.2020.1768410] [PMID: 32447981]
[30]
Yu, Y.; Dong, Y.; Deng, B.; Yang, T. IncRNA MIAT accelerates keloid formation by miR-411-5p/JAG1 axis. Crit. Rev. Eukaryot. Gene Expr., 2023, 33(2), 81-92.
[http://dx.doi.org/10.1615/CritRevEukaryotGeneExpr.2022044734] [PMID: 36734859]
[31]
Qu, X.; Du, Y.; Shu, Y.; Gao, M.; Sun, F.; Luo, S.; Yang, T.; Zhan, L.; Yuan, Y.; Chu, W.; Pan, Z.; Wang, Z.; Yang, B.; Lu, Y. MIAT is a pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium. Sci. Rep., 2017, 7(1), 42657.
[http://dx.doi.org/10.1038/srep42657] [PMID: 28198439]
[32]
Yao, L.; Zhou, B.; You, L.; Hu, H.; Xie, R. LncRNA MIAT/miR-133a-3p axis regulates atrial fibrillation and atrial fibrillation-induced myocardial fibrosis. Mol. Biol. Rep., 2020, 47(4), 2605-2617.
[http://dx.doi.org/10.1007/s11033-020-05347-0] [PMID: 32130618]
[33]
García-Padilla, C.; Domínguez, J.N.; Aránega, A.E.; Franco, D. Differential chamber-specific expression and regulation of long non-coding RNAs during cardiac development. Biochim. Biophys. Acta. Gene Regul. Mech., 2019, 1862(10), 194435.
[http://dx.doi.org/10.1016/j.bbagrm.2019.194435] [PMID: 31678627]
[34]
Xiao, W.; Zheng, D.; Chen, X.; Yu, B.; Deng, K.; Ma, J.; Wen, X.; Hu, Y.; Hou, J. Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214-3p. iScience, 2021, 24(12), 103518.
[http://dx.doi.org/10.1016/j.isci.2021.103518] [PMID: 34950859]
[35]
Tao, P.; Ji, J.; Wang, Q.; Cui, M.; Cao, M.; Xu, Y. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease. Front. Immunol., 2022, 13, 1080456.
[http://dx.doi.org/10.3389/fimmu.2022.1080456] [PMID: 36601125]
[36]
Wang, X.; Zhao, J.; Li, Y.; Rao, J.; Xu, G. Epigenetics and endoplasmic reticulum in podocytopathy during diabetic nephropathy progression. Front. Immunol., 2022, 13, 1090989.
[http://dx.doi.org/10.3389/fimmu.2022.1090989] [PMID: 36618403]
[37]
Rayego-Mateos, S.; Rodrigues-Diez, R.R.; Fernandez-Fernandez, B.; Mora-Fernández, C.; Marchant, V.; Donate- Correa, J.; Navarro-González, J.F.; Ortiz, A.; Ruiz-Ortega, M. Targeting inflammation to treat diabetic kidney disease: The road to 2030. Kidney Int., 2023, 103(2), 282-296.
[http://dx.doi.org/10.1016/j.kint.2022.10.030] [PMID: 36470394]
[38]
Forst, T.; Mathieu, C.; Giorgino, F.; Wheeler, D.C.; Papanas, N.; Schmieder, R.E.; Halabi, A.; Schnell, O.; Streckbein, M.; Tuttle, K.R. New strategies to improve clinical outcomes for diabetic kidney disease. BMC Med., 2022, 20(1), 337.
[http://dx.doi.org/10.1186/s12916-022-02539-2] [PMID: 36210442]
[39]
Akhtar, M.; Taha, N.M.; Nauman, A.; Mujeeb, I.B.; Al-Nabet, A.D.M.H. Diabetic kidney disease: Past and present. Adv. Anat. Pathol., 2020, 27(2), 87-97.
[http://dx.doi.org/10.1097/PAP.0000000000000257] [PMID: 31876542]
[40]
Zhao, Y.; Yan, G.; Mi, J.; Wang, G.; Yu, M.; Jin, D.; Tong, X.; Wang, X. The impact of lncRNA on diabetic kidney disease: Systematic review and in silico analyses. Comput. Intell. Neurosci., 2022, 2022, 1-17.
[http://dx.doi.org/10.1155/2022/8400106] [PMID: 35528328]
[41]
Ghafouri-Fard, S.; Abak, A.; Talebi, S.F.; Shoorei, H.; Branicki, W.; Taheri, M.; Akbari Dilmaghani, N. Role of miRNA and lncRNAs in organ fibrosis and aging. Biomed. Pharmacother., 2021, 143, 112132.
[http://dx.doi.org/10.1016/j.biopha.2021.112132] [PMID: 34481379]
[42]
Wang, Z.; Zhang, B.; Chen, Z.; He, Y.; Ru, F.; Liu, P.; Chen, X. The long noncoding RNA myocardial infarction-associated transcript modulates the epithelial-mesenchymal transition in renal interstitial fibrosis. Life Sci., 2020, 241, 117187.
[http://dx.doi.org/10.1016/j.lfs.2019.117187] [PMID: 31863776]
[43]
Liu, Y.; Xu, Z.; Ma, F.; Jia, Y.; Wang, G. Knockdown of TLR4 attenuates high glucose-induced podocyte injury via the NALP3/ASC/Caspase-1 signaling pathway. Biomed. Pharmacother., 2018, 107, 1393-1401.
[http://dx.doi.org/10.1016/j.biopha.2018.08.134] [PMID: 30257355]
[44]
Zhang, M.; Zhao, S.; Xu, C.; Shen, Y.; Huang, J.; Shen, S.; Li, Y.; Chen, X. Ablation of lncRNA MIAT mitigates high glucose-stimulated inflammation and apoptosis of podocyte via miR-130a-3p/TLR4 signaling axis. Biochem. Biophys. Res. Commun., 2020, 533(3), 429-436.
[http://dx.doi.org/10.1016/j.bbrc.2020.09.034] [PMID: 32972755]
[45]
Tan, T.E.; Wong, T.Y. Diabetic retinopathy: Looking forward to 2030. Front. Endocrinol., 2023, 13, 1077669.
[http://dx.doi.org/10.3389/fendo.2022.1077669] [PMID: 36699020]
[46]
Teo, Z.L.; Tham, Y.C.; Yu, M.; Chee, M.L.; Rim, T.H.; Cheung, N.; Bikbov, M.M.; Wang, Y.X.; Tang, Y.; Lu, Y.; Wong, I.Y.; Ting, D.S.W.; Tan, G.S.W.; Jonas, J.B.; Sabanayagam, C.; Wong, T.Y.; Cheng, C.Y. Global prevalence of diabetic retinopathy and projection of burden through 2045. Ophthalmology., 2021, 128(11), 1580-1591.
[http://dx.doi.org/10.1016/j.ophtha.2021.04.027] [PMID: 33940045]
[47]
Cai, C.; Meng, C.; He, S.; Gu, C.; Lhamo, T.; Draga, D.; Luo, D.; Qiu, Q. DNA methylation in diabetic retinopathy: Pathogenetic role and potential therapeutic targets. Cell Biosci., 2022, 12(1), 186.
[http://dx.doi.org/10.1186/s13578-022-00927-y] [PMID: 36397159]
[48]
Elafros, M.A.; Callaghan, B.C.; Skolarus, L.E.; Vileikyte, L.; Lawrenson, J.G.; Feldman, E.L. Patient and health care provider knowledge of diabetes and diabetic microvascular complications: A comprehensive literature review. Rev. Endocr. Metab. Disord., 2022, 24(2), 221-239.
[http://dx.doi.org/10.1007/s11154-022-09754-5] [PMID: 36322296]
[49]
Yue, T.; Shi, Y.; Luo, S.; Weng, J.; Wu, Y.; Zheng, X. The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Front. Immunol., 2022, 13, 1055087.
[http://dx.doi.org/10.3389/fimmu.2022.1055087] [PMID: 36582230]
[50]
Kaur, P.; Kotru, S.; Singh, S.; Munshi, A. Role of miRNAs in diabetic neuropathy: Mechanisms and possible interventions. Mol. Neurobiol., 2022, 59(3), 1836-1849.
[http://dx.doi.org/10.1007/s12035-021-02662-w] [PMID: 35023058]
[51]
Alves, C.H.; Fernandes, R.; Santiago, A.R.; Ambrósio, A.F. Microglia contribution to the regulation of the retinal and choroidal vasculature in age-related macular degeneration. Cells., 2020, 9(5), 1217.
[http://dx.doi.org/10.3390/cells9051217] [PMID: 32423062]
[52]
Zhang, J.; Chen, M.; Chen, J.; Lin, S.; Cai, D.; Chen, C.; Chen, Z. Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis. Biosci. Rep., 2017, 37(2), BSR20170036.
[http://dx.doi.org/10.1042/BSR20170036] [PMID: 28246353]
[53]
Yan, B.; Yao, J.; Liu, J.Y.; Li, X.M.; Wang, X.Q.; Li, Y.J.; Tao, Z.F.; Song, Y.C.; Chen, Q.; Jiang, Q. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ. Res., 2015, 116(7), 1143-1156.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.305510] [PMID: 25587098]
[54]
Yu, X.; Ma, X.; Lin, W.; Xu, Q.; Zhou, H.; Kuang, H. Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by modulating miR-342–3p targeting of CASP1 in diabetic retinopathy. Exp. Eye Res., 2021, 202, 108300.
[http://dx.doi.org/10.1016/j.exer.2020.108300] [PMID: 33065089]
[55]
Biswas, S.; Coyle, A.; Chen, S.; Gostimir, M.; Gonder, J.; Chakrabarti, S. Expressions of serum lncRNAs in diabetic retinopathy – a potential diagnostic tool. Front. Endocrinol., 2022, 13, 851967.
[http://dx.doi.org/10.3389/fendo.2022.851967] [PMID: 35464068]
[56]
Cao, W.; Zhang, N.; He, X.; Xing, Y.; Yang, N. Long non- coding RNAs in retinal neovascularization: current research and future directions. Graefes Arch. Clin. Exp. Ophthalmol., 2022.
[http://dx.doi.org/10.1007/s00417-022-05843-y] [PMID: 36171459]
[57]
Zhu, X.; Li, Q.; George, V.; Spanoudis, C.; Gilkes, C.; Shrestha, N.; Liu, B.; Kong, L.; You, L.; Echeverri, C.; Li, L.; Wang, Z.; Chaturvedi, P.; Muniz, G.J.; Egan, J.O.; Rhode, P.R.; Wong, H.C. A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice. Front. Immunol., 2023, 14, 1114802.
[http://dx.doi.org/10.3389/fimmu.2023.1114802] [PMID: 36761778]
[58]
Xu, S.; Pelisek, J.; Jin, Z.G. Atherosclerosis is an epigenetic disease. Trends Endocrinol. Metab., 2018, 29(11), 739-742.
[http://dx.doi.org/10.1016/j.tem.2018.04.007] [PMID: 29753613]
[59]
Fasolo, F.; Jin, H.; Winski, G.; Chernogubova, E.; Pauli, J.; Winter, H.; Li, D.Y.; Glukha, N.; Bauer, S.; Metschl, S.; Wu, Z.; Koschinsky, M.L.; Reilly, M.; Pelisek, J.; Kempf, W.; Eckstein, H.H.; Soehnlein, O.; Matic, L.; Hedin, U.; Bäcklund, A.; Bergmark, C.; Paloschi, V.; Maegdefessel, L. Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization. Circulation., 2021, 144(19), 1567-1583.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.052023] [PMID: 34647815]
[60]
Wu, L.; Pei, Y.; Zhu, Y.; Jiang, M.; Wang, C.; Cui, W.; Zhang, D. Association of N6-methyladenine DNA with plaque progression in atherosclerosis via myocardial infarction-associated transcripts. Cell Death Dis., 2019, 10(12), 909.
[http://dx.doi.org/10.1038/s41419-019-2152-6] [PMID: 31797919]
[61]
Sun, G.; Li, Y.; Ji, Z. Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K/Akt signaling pathway. Drug Deliv., 2019, 26(1), 641-649.
[http://dx.doi.org/10.1080/10717544.2019.1628116] [PMID: 31237148]
[62]
Zhou, Y.; Ma, W.; Bian, H.; Chen, Y.; Li, T.; Shang, D.; Sun, H. Long non-coding RNA MIAT/miR-148b/PAPPA axis modifies cell proliferation and migration in ox-LDL-induced human aorta vascular smooth muscle cells. Life Sci., 2020, 256, 117852.
[http://dx.doi.org/10.1016/j.lfs.2020.117852] [PMID: 32470448]
[63]
Han, X.; Cai, L.; Shi, Y.; Hua, Z.; Lu, Y.; Li, D.; Yang, J. Integrated analysis of long non-coding RNA-mRNA profile and validation in diabetic cataract. Curr. Eye Res., 2022, 47(3), 382-390.
[http://dx.doi.org/10.1080/02713683.2021.1984536] [PMID: 35068271]
[64]
Meydan, C.; Üçeyler, N.; Soreq, H. Non-coding RNA regulators of diabetic polyneuropathy. Neurosci. Lett., 2020, 731, 135058.
[http://dx.doi.org/10.1016/j.neulet.2020.135058] [PMID: 32454150]
[65]
Meydan, C.; Bekenstein, U.; Soreq, H. Molecular regulatory pathways link sepsis with metabolic syndrome: Non- coding RNA elements underlying the sepsis/metabolic cross-talk. Front. Mol. Neurosci., 2018, 11, 189.
[http://dx.doi.org/10.3389/fnmol.2018.00189] [PMID: 29922126]
[66]
Huo, W.; Hou, Y.; Li, Y.; Li, H. Downregulated lncRNA-MIAT confers protection against erectile dysfunction by downregulating lipoprotein lipase via activation of miR-328a-5p in diabetic rats. Biochim. Biophys. Acta Mol. Basis Dis., 2019, 1865(6), 1226-1240.
[http://dx.doi.org/10.1016/j.bbadis.2019.01.018] [PMID: 30660685]

Rights & Permissions Print Cite
Article Metrics
27
2
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy